MarketCap
Facebook
X
Telegram
Hutchison China MediTech Limited Income Statement 2025-2011 | HCM
Brief overview of financial results at Hutchison China MediTech Limited
The overview follows changes across a five-year period. Hutchison China MediTech Limited reported revenue of 228 million dollars in 2020 and 549 million dollars by 2025. The total change was +140.6%, with a CAGR of approximately 19.2%. Revenue followed a strong upward trend without signs of stagnation.
Gross profit was 39.5 million dollars at the start and 212 million dollars at the end of the period (+437.7%). Direct costs outpaced revenue, limiting the benefit of changes in sales. The gross margin was 17.3% at the start and 38.7% at the end. The margin shift points to a more favorable sales-and-cost structure.
EBITDA changed from −191 million dollars to −25.9 million dollars (+86.4%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin moved from −83.6% to −4.7%. The increased EBITDA share is a positive sign.
Comparing the endpoints shows a move from −126 million dollars to 457 million dollars. The business moved out of a loss and ended the period with a profit.
Market capitalization changed from 20.1 billion dollars to 12 billion dollars (−40.2%). Financial performance is stronger than the share-price trend.
Overall conclusion
The figures do not all move in the same direction. Key strengths include improving net profitability, a larger revenue base and better sales economics. The main areas of concern are a low EBITDA margin and a weaker market valuation. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Hutchison China MediTech Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
12 B | 12.8 B | 12.8 B | 11.3 B | 21.6 B | 20.1 B | 15.5 B | 17.3 B | 20.8 B | 843 M | - | - | - | - | - |
Shares |
858 M | 855 M | 850 M | 847 M | 793 M | 698 M | 666 M | 664 M | 617 M | 59.7 M | - | - | - | - | - |
Historical Prices |
14 | 15 | 15.1 | 13.3 | 27.2 | 28.7 | 23.3 | 26.1 | 33.7 | 12.7 | - | - | - | - | - |
Net Income |
457 M | 37.7 M | 101 M | -361 M | -195 M | -126 M | -106 M | -74.8 M | -26.7 M | -43 M | 7.99 M | 5.37 M | 5.92 M | 3.64 M | 710 K |
Revenue |
549 M | 630 M | 838 M | 426 M | 356 M | 228 M | 205 M | 214 M | 241 M | 216 M | 178 M | 91.8 M | 46 M | 195 M | 167 M |
Cost of Revenue |
336 M | 349 M | 384 M | 311 M | 91.6 M | 63.5 M | 46.2 M | 35.3 M | 24.8 M | 21.7 M | 17.3 M | - | - | - | - |
Gross Profit |
- | - | - | - | - | 39.5 M | 205 M | 214 M | 241 M | 216 M | 67.4 M | 19.8 M | 23.8 M | 96 M | 92.8 M |
Operating Income |
-39.2 M | -43.7 M | 18.4 M | -408 M | -328 M | -197 M | -146 M | -92.6 M | -53.4 M | -46.7 M | -9.77 M | -18.3 M | - | - | - |
Interest Expense |
- | - | 759 K | 652 K | 592 K | 787 K | 1.03 M | 1.01 M | 1.46 M | 1.63 M | 1.4 M | 1.52 M | - | - | - |
EBITDA |
-25.9 M | -31.4 M | 26.6 M | -399 M | -321 M | -191 M | -141 M | -89.1 M | -50.8 M | -46.7 M | -7.76 M | -5.92 M | -87 K | 2.64 M | 9.91 M |
Operating Expenses |
- | - | - | - | - | 236 M | 190 M | 163 M | 119 M | 106 M | 77.2 M | 26.9 M | 24.8 M | 97.4 M | 87.2 M |
General and Administrative Expenses |
66.7 M | 64.3 M | 79.8 M | 92.2 M | 89.3 M | 50 M | 39.2 M | 30.9 M | 24 M | - | 19.6 M | 22.6 M | 21.3 M | 35.7 M | - |
All numbers in USD currency
Quarterly Income Statement Hutchison China MediTech Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
858 M | 857 M | 855 M | 856 M | 850 M | 847 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 665 M | - | - | - | 664 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
457 M | 455 M | 37.7 M | 25.8 M | 101 M | 169 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.9 M | - | - | - | -11.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
549 M | 278 M | 630 M | 306 M | 838 M | 533 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.2 M | - | - | - | 52.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
336 M | 168 M | 349 M | 36.9 M | 384 M | 45.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.3 M | - | - | - | 7.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-39.2 M | -3.51 M | -43.7 M | -27.5 M | 18.4 M | 112 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -36 M | - | - | - | -25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | 21.6 M | - | 1.48 M | 759 K | 224 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 260 K | - | - | - | 206 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-25.9 M | 2.6 M | -31.4 M | -21.3 M | 26.6 M | 115 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.8 M | - | - | - | -24.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
66.7 M | 27.8 M | 64.3 M | 30.5 M | 79.8 M | 41.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.2 M | - | - | - | 7.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Hutchison China MediTech Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
